0 173

Cited 8 times in

Comparing the Effectiveness and Safety of the Addition of and Switching to Aripiprazole for Resolving Antipsychotic-Induced Hyperprolactinemia: A Multicenter, Open-Label, Prospective Study

 Yoon, Hui Woo  ;  Lee, Jung Suk  ;  Park, Sang Jin  ;  Lee, Seon-Koo  ;  Choi, Won-Jung  ;  Kim, Tae Yong  ;  Hong, Chang Hyung  ;  Seok, Jeong-Ho  ;  Park, Il-Ho  ;  Son, Sang Joon  ;  Roh, Daeyoung  ;  Kim, Bo-Ra  ;  Lee, Byung Ook 
 CLINICAL NEUROPHARMACOLOGY, Vol.39(6) : 288-294, 2016 
Journal Title
Issue Date
OBJECTIVES: Hyperprolactinemia is an important but often overlooked adverse effect of antipsychotics. Several studies have shown that switching to or adding aripiprazole normalizes antipsychotic-induced hyperprolactinemia. However, no study has directly compared the effectiveness and safety of the 2 strategies. METHODS: A total of 52 patients with antipsychotic-induced hyperprolactinemia were recruited. Aripiprazole was administered to patients with mild hyperprolactinemia (serum prolactin level < 50 ng/mL). Patients with severe hyperprolactinemia (serum prolactin level > 50 ng/mL) were randomized to an aripiprazole-addition group (adding aripiprazole to previous antipsychotics) or a switching group (switching previous antipsychotics to aripiprazole). Serum prolactin level, menstrual disturbances, sexual dysfunction, psychopathologies, and quality of life were measured at weeks 0, 1, 2, 4, 6, and 8. RESULTS: Both the addition and switching groups showed significantly reduced serum prolactin level and menstrual disturbances and improved sexual dysfunction. In patients with severe hyperprolactinemia, the numbers of patients with hyperprolactinemia and menstrual disturbance in the switching group were significantly lower than those in the addition group at week 8. CONCLUSIONS: Both the addition and switching strategies were effective in resolving antipsychotic-induced hyperprolactinemia and hyperprolactinemia-related adverse events, including menstrual disturbances and sexual dysfunction. In addition, these findings suggest that switching to aripiprazole may be more effective than addition of aripiprazole for normalizing hyperprolactinemia and improving hyperprolactinemia-related adverse events in patients with schizophrenia.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Psychiatry (정신과학교실) > 1. Journal Papers
Yonsei Authors
Seok, Jeong Ho(석정호) ORCID logo https://orcid.org/0000-0002-9402-7591
Yoon, Hui Woo(윤희우)
Lee, Jung Suk(이정석)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.